1. Home
  2. GLPG vs ADUS Comparison

GLPG vs ADUS Comparison

Compare GLPG & ADUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$32.62

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Logo Addus HomeCare Corporation

ADUS

Addus HomeCare Corporation

HOLD

Current Price

$108.89

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLPG
ADUS
Founded
1999
1979
Country
Belgium
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
2005
2009

Fundamental Metrics

Financial Performance
Metric
GLPG
ADUS
Price
$32.62
$108.89
Analyst Decision
Hold
Buy
Analyst Count
4
11
Target Price
$31.33
$138.73
AVG Volume (30 Days)
90.2K
163.0K
Earning Date
02-11-2026
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
6.76
EPS
N/A
4.66
Revenue
$336,643,201.00
$1,346,596,000.00
Revenue This Year
$1.76
$25.50
Revenue Next Year
$0.49
$7.11
P/E Ratio
N/A
$23.62
Revenue Growth
10.31
18.77
52 Week Low
$22.36
$88.96
52 Week High
$37.78
$136.72

Technical Indicators

Market Signals
Indicator
GLPG
ADUS
Relative Strength Index (RSI) 56.99 37.32
Support Level $32.65 $110.12
Resistance Level $33.23 $111.57
Average True Range (ATR) 0.63 2.36
MACD 0.14 -0.46
Stochastic Oscillator 73.16 9.46

Price Performance

Historical Comparison
GLPG
ADUS

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

About ADUS Addus HomeCare Corporation

Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, mainly to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are medical in nature to those individuals who may require assistance during an illness or after surgery.

Share on Social Networks: